Menu
Recruiting NCT07338604

Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Early Phase I Interventional Hematolymphoid Malignancies

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CAR-T cell infusion, UTAA07 injection.
Who it may be relevant to
Registry conditions: Hematolymphoid Malignancies. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinical Study of UTAA07 Injection in the Treatment of CD7 Positive Adult Relapsed/Refractory Hematologic and Lymphatic Systemic Malignancies

Overview

This is a single-arm, open-label study designed to evaluate the safety, tolerability and cellular pharmacokinetic profiles of UTAA07 Injection. It also aims to preliminarily assess the efficacy of the investigational drug in subjects with relapsed/refractory hematolymphoid malignancies, so as to identify the optimal dose for subsequent formal clinical trials.

Detailed description

This is a single-arm, open-label study designed to investigate the safety, tolerability, and cellular kinetic characteristics of the investigational product. Additionally, it aims to preliminarily observe the efficacy of the investigational product in subjects with relapsed/refractory hematological and lymphoid malignancies, so as to explore the optimal dose for formal clinical applications.

Three dose cohorts are planned, namely 2×10⁹ CAR-γδT cells, 4×10⁹ CAR-γδT cells, and 6×10⁹ CAR-γδT cells. Additional dose cohorts may be added at the discretion of the investigator and/or collaborating institutions. The study will adopt a 3+3 dose escalation/de-escalation schema.

Interventions

  • Drug CAR-T cell infusion
    CAR-T cell infusion
  • Drug UTAA07 injection
    UTAA07 Injection is a chimeric antigen receptor (CAR)-engineered γδ T-cell product that targets the CD7 antigen expressed on the surface of tumor cells.

Primary outcome measures

  • Adverse Events [Time frame: 24 months]

Eligibility criteria

Inclusion criteria

  • Aged ≥ 18 years, regardless of gender.
  • Expected survival time ≥ 3 months.
  • ECOG performance status score of 0-1.
  • Confirmed diagnosis of relapsed/refractory CD7-positive hematolymphoid malignancies at screening.
  • Coagulation function, liver and kidney function, and cardiopulmonary function meeting the requirements.
  • Ability to understand the trial and signed informed consent form.

Exclusion criteria

  • A history of malignant tumors other than hematolymphoid malignancies within 5 years prior to screening, excluding carcinoma in situ.
  • Positive results for virological tests or syphilis.
  • Severe cardiac diseases.
  • Unstable systemic diseases as determined by the investigator.
  • Active or uncontrolled infections requiring systemic treatment within 7 days prior to screening, excluding mild urinary and reproductive system infections and upper respiratory tract infections.
  • Pregnant or lactating women; female subjects planning to become pregnant within 2 years after cell infusion; or male subjects whose partners plan to become pregnant within 2 years after the subject's cell infusion.
  • Subjects receiving systemic corticosteroid therapy within 7 days prior to screening, or those judged by the investigator to require long-term systemic corticosteroid therapy during the trial period, excluding inhaled or topical administration.
  • Participation in other clinical studies within 1 month prior to screening.
  • Evidence of central nervous system (CNS) involvement at screening, such as detection of tumor cells in cerebrospinal fluid (CSF) or imaging findings suggestive of CNS infiltration.
  • Patients requiring long-term use of immunosuppressants as determined by the investigator at screening.
  • A history of epilepsy or other central nervous system diseases.
  • Patients with primary immunodeficiency diseases.
  • Other circumstances deemed inappropriate for enrollment by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Affiliated Hospital of Soochow University — Suzhou

Publications

  • You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia/lymphoma. Am J Clin Pathol. 2015 Sep;144(3):411-22. doi: 10.1309/AJCPMF03LVSBLHPJ. PMID 26276771

Identifiers

NCT: NCT07338604 · PG-004-3

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗